ABSTRACT

Objective: Polycystic ovary syndrome(PCOS) is the most common hormonal disorder which mostly affects women of childbearing ages. Almost,women with this syndrome, insulin sensitizing drugs can have both beneficial hormonal and biochemical effects. Hence, the objective of this research was to assess and compare the effects of insulin sensitizing drug, rosiglitazone, on hormonal and biochemical profiles in patients with PCOS.

Methods: In this simple randomization study, approximately, one hundred and twenty subjects were enrolled in this study, they were divided into two groups of 60 subjects each. The patients' group were received rosiglitazone treatment for three months (4-5mg/day) and the other 60 were the control group which included apparently healthy volunteers. Hormonal profiles (serum testosterone, serum insulin, HOMA-IR and serum resistin) and biochemical profiles (fasting serum glucose and lipid profile), in addition to body weight, height, body mass index, and even blood pressure were evaluated before and after treatment for both the patient and control groups.

Results: The current study found a that there was a significant increase in the mean of body mass index (BMI), serum levels of glucose, insulin, testosterone, resistin, lipid profile (TC, HDL, LDL, TG) in addition to systolic and diastolic blood pressure in women with PCOS prior to rosiglitazone in comparison to controls. Whereas after drug therapy the patient experienced a significant decrease in all of the studied parameters associated with insulin resistance improvement, as well as a nonsignificant decrease in serum testosterone level.

Conclusion: This study found that treating women with PCOS with rosiglitazone resulted in a decrease in hormonal profiles of serum insulin and serum testosterone, as well as an improvement in metabolic profiles, indicating the potential benefit of this drug in the treatment of PCOS patients.

Keywords: Polycystic ovary syndrome; Rosiglitazone, insulin resistance, serum glucose, ,BMI, testosterone, lipid profile, resistin.